Form 4: Tvardi Therapeutics Director Sujal Shah Reports Stock Option Transactions

Director Sujal Shah reports acquisition and disposal of stock options in Tvardi Therapeutics following a merger, according to a Form 4 filing.

Summary

• Sujal Shah, a director of Tvardi Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
• The report indicates transactions related to stock options following the merger of Cara Therapeutics, Inc. with CT Convergence Merger Sub, Inc., resulting in Tvardi Therapeutics, Inc.
• Shah acquired stock options to purchase 10,394 shares at an exercise price of $0.68, fully vested and exercisable from January 29, 2031.
• These options were received in exchange for options to acquire 77,500 shares of Legacy Tvardi common stock at $0.09 per share, as part of the merger agreement.
• Additionally, Shah acquired options to purchase 8,047 shares at an exercise price of $4.7, vesting over 37 months from the vesting commencement date, exercisable from December 15, 2031.
• These options were received in exchange for options to acquire 60,000 shares of Legacy Tvardi common stock at $0.63 per share, also pursuant to the merger agreement.
• The transactions occurred on April 15, 2025.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing, so the sentiment is neutral.

Positives

• The director's acquisition of stock options could be interpreted as a sign of confidence in the company's future performance.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedules of the options suggest a long-term perspective.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• The filing provides transparency to shareholders regarding insider transactions.

Key Dates

Keywords

Form 4, Tvardi Therapeutics, Stock Options, Beneficial Ownership, Merger, Director, Sujal Shah